Zemisen

Zemisen is a clinical-stage biotechnology company based in South Korea that specializes in the development of next-generation immuno-oncology therapies. The company's primary focus is on modulating the adenosine pathway within the tumor microenvironment, specifically targeting the enzymes CD39 and CD73 which are critical for tumor-mediated immunosuppression. By developing potent monoclonal antibodies against these targets, Zemisen seeks to transform the tumor microenvironment from immunosuppressive to immuno-stimulatory, thereby enhancing anti-tumor immune responses. Their lead candidate, ZM-101, is an anti-CD39 monoclonal antibody currently being evaluated in early-stage clinical trials for the treatment of advanced solid tumors. The company aims to provide novel treatment options for patients who are non-responsive to current checkpoint inhibitors.